ALTIMMUNE, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
ALTIMMUNE, INC. (ALT) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.76% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-02-27
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.76%, a 126.21% decline from fiscal 2023.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 2.90%, a 1280.95% increase from fiscal 2022.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.21%.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was -0.47%, a 262.07% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -0.76% 10-K · filed 2025-02-27 | |
| 2023-12-31 | 2.90% 10-K · filed 2025-02-27 | |
| 2022-12-31 | 0.21% 10-K · filed 2024-03-27 | |
| 2021-12-31 | -0.47% 10-K · filed 2023-02-28 | |
| 2020-12-31 | 0.29% 10-K · filed 2022-03-15 | |
| 2019-12-31 | -2.81% 10-K · filed 2021-02-25 | -0.99% 10-K · filed 2020-03-27 |
| 2018-12-31 | 2.14% 10-K · filed 2020-03-27 | |
| 2017-12-31 | -0.78% 10-K · filed 2019-04-01 | |
| 2016-12-31 | -6.34% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |